Health Tech Capitol | Cellectar snags $2 million contract
15464
post-template-default,single,single-post,postid-15464,single-format-standard,tribe-no-js,tribe-bar-is-disabled,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-9.3,wpb-js-composer js-comp-ver-4.12,vc_responsive

Cellectar snags $2 million contract

03 Aug Cellectar snags $2 million contract

Posted at 14:00h in Uncategorized by
0 Likes

Cellectar Biosciences Inc., a Madison developer of cancer treatment and diagnostic drugs, said Wednesday it has received $2 million from the National Cancer Institute to support a clinical study of its leading drug candidate.

The drug candidate uses ionizing radiation and has potential to treat hematologic malignancies, including multiple myeloma, the company said in a news release. The money represents the second phase of a Fast-Track Small Business Innovation Research, or SBIR, grant.

Read more at the Milwaukee Journal Sentinel

No Comments

Sorry, the comment form is closed at this time.